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Abstract
Excess intake of sodium, a common problem worldwide, is associated with hypertension and 
cardiovascular disease (CVD), while hypertension is a major risk factor for CVD. Population-wide 
efforts to reduce sodium intake have been identified as a promising strategy for preventing 
hypertension and CVD, and such initiatives are currently recommended by a variety of scientific 
and public health organizations. By reviewing the literature published from January 2011 to 
March 2013, we summarized recent economic evidence on interventions to reduce sodium intake. 
The evidence supports population-wide interventions for reducing sodium intake worldwide. Both 
lowering the salt content in manufactured foods and conducting mass media campaigns at national 
level are cost-effective in preventing CVD. Although better data on the cost of interventions is 
needed for rigorous economic evaluations, population-wide sodium reduction can be a promising 
approach for containing the growing health and economic burden associated with hypertension 
and its sequelae.
Keywords
Salt intake; sodium; cardiovascular disease; costs; hypertension; interventions
Introduction
In 2008, cardiovascular disease (CVD), the number one cause of death in the world, 
accounted for an estimated 17.3 million deaths, or 30% of all deaths in that year [1]. 
Furthermore, CVD is projected to remain the leading cause of death worldwide in the next 
several decades [2]. All told, low- and middle-income countries experienced over 80% of all 
CVD deaths in 2008 [1], while the economic burden of CVD in developed countries 
continues to be staggering. Indeed, the annual cost of CVD in the United States (US) was 
conservatively estimated for 2009 at $312.6 billion [3]. In the European Union, an analysis 
found that CVD cost 169 billion euros in 2003, with 62% of these costs for health care, 21% 
for loss of productivity, and 17% for informal care [4]. In the United Kingdom (UK) alone, 
CVD cost 29.1 billion pounds (about $53.0 billion) in 2004, 29% of which was for coronary 
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heart disease and 27% for cerebrovascular disease [5]. Globally, the most important risk 
factor for CVD is hypertension while suboptimal blood pressure (systolic blood pressure ≥ 
115 mmHg) is responsible for an estimated 62% of strokes and 49% of coronary heart 
diseases worldwide [6]. The economic burden of hypertension ranged 5−15% of the gross 
domestic product (GDP) in developed countries and 2.5−8.0% of GDP in developing 
countries [7]. These alarming statistics, combined with ageing population and the growth in 
major risk factors such as obesity and physical inactivity, have caught the attention of global 
leaders, and in 2011 the United Nations called for setting a new international agenda on 
noncommunicable diseases, like heart disease and stroke, and a focus on major risk factors 
like high intake of salt and the use of tobacco [8].
Reducing sodium intake has repeatedly been documented effective in lowering risk of CVD 
and hypertension [9–22] although some literature still questioned the validity of universal 
reduction of sodium intake [23, 24]. In fact, initiatives promoting a reduction in sodium 
intake began as early as the 1970s, and there are success stories in Finland and the UK [18, 
25, 26]. In the US, efforts to reduce sodium started as early as 1969, when at the White 
House Conference on Food, Nutrition and Health, excess sodium intake was linked to 
hypertension [27], and since the 1980s, advice has been consistent that the public should 
reduce salt intake [18]. Recently actions in North America have accelerated. In April 2010, 
the Institute of Medicine released a report on strategies to reduce sodium intake in the US 
[28], and in May 2013 released sodium intake in population: assessment of evidence [24]; in 
Canada, in 2010, the federal and provincial governments agreed to an interim target of 5.75 
g/day salt by 2016 [29]. Similarly, in developing countries, sodium reduction has been on 
the public health priority agenda. In February 2010, the Pan American Health Organization
−World Health Organization (WHO) regional expert group on preventing CVD through the 
reduction of dietary salt outlined its recommendations for a population-based approach. In 
September 2011, South Africa set a target to reduce salt intake to <5 g/person/day (~2000 
mg sodium/person/day) by the year 2020 through a public health campaign and by 
regulating the food industry [14]. Irrespective of the initiatives already under way, economic 
analysis can help inform selection of intervention strategies for reducing salt intake. This 
summary of the current status of economic evaluation of sodium reduction to prevent CVD 
can be helpful in informing current initiatives, and revising current interventions or 
developing new ones to improve cost-effectiveness. Appropriately designed interventions to 
reduce sodium intake should improve public health by reducing the growing burden of 
hypertension and CVD worldwide.
Major types of economic evaluations of preventing CVD by reducing 
sodium intake
The presence of a public health problem is not a sufficient justification for public 
intervention. First, the societal costs of the intervention should be less than its expected 
social benefits. Second, because resources are limited, even if the costs are lower than the 
benefits, there is still often a need to compare these costs and benefits with those of other 
interventions to judge whether the possible investment in the intervention being considered 
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is the best use of resources [30–32]. Accordingly, not all potentially beneficial interventions 
can be funded and/or implemented, i.e., choices must be made in allocating scarce resources.
Figure 1 depicts the linkages between the 5 major types of economic evaluation and the 
impact of interventions to reduce sodium intake for the purpose of preventing CVD. For any 
kind of intervention, the most basic economic evaluation is a cost analysis, although 
researchers often start with a cost-of-illness study. As the evaluation of interventions 
become more detailed, however, the need to consider the cost of the intervention will 
become more apparent. In fact, cost analysis is an important component of all economic 
evaluations and often serves as the foundation for all other kinds of economic evaluations 
[33].
The 3 other types of economic evaluation shown in Figure 1 link the costs (either of the 
intervention, the illness, or both) with health outcomes from interventions. Because health 
outcomes are often measured by the number of diseases or deaths averted (CVD’s averted in 
Figure 1), one natural way of linking the costs of intervention with the health outcomes is 
the cost per case averted or per death avoided. This is done in a typical cost-effectiveness 
analysis, and it is often measured by a cost-effectiveness ratio derived by dividing the costs 
of the intervention by the incremental health outcomes associated with that intervention. 
Another type of analysis, called cost-utility analysis, links the cost of intervention to the 
number of life years gained from the intervention. Here, the number of life years gained is 
often measured by quality-adjusted life years (QALYs) or disability-adjusted life years 
(DALYs) to produce standardized measures. The validity of both QALYs and DALYs is 
debatable, however, and their use in economic evaluations should be approached with 
caution [34].
If the number of cases of the disease in question or the deaths averted can be measured or 
converted to monetary terms, the linkage between the costs of the intervention and health 
outcomes can be expressed as a cost-benefit analysis. The cost-benefit ratio is derived by 
dividing the costs of the intervention by the incremental monetized health outcomes. 
Alternatively, researchers can look at the net benefit, which simply is the difference between 
total benefits from the intervention and its costs. In the cost-benefit analysis, because there 
are no natural prices for health and human life, artificial prices must be created by methods 
such as willingness to pay. More often than not, however, valuing human life and health in 
monetary terms is a challenging issue to researchers as well as to the public [35].
Recent economic evaluations of interventions to prevent cardiovascular 
disease through sodium reduction
Identifying the literature
Using the search terms sodium, salt, dietary, and sodium chloride combined with the terms 
economics, costs, health care expenditure, health care costs, cost analysis, cost-
effectiveness, cost-benefit, cost-utility, and economic aspects of illness, we searched 6 
databases and found 91 potentially relevant articles published in English during the period of 
January 2011 to March 2013: PubMed, n=24; ABI Inform, n=17; EconLit, n=10; Cinahl, 
n=21; Embase, n=10; and WOS, n=9. After screening them to remove obviously irrelevant 
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articles, reviews, commentary, duplicates, and articles not related to CVD, we identified 5 
original research articles for the present review. In addition, we identified a publication of 
apparent relevance that was written in Spanish but had an English abstract. With that 
abstract and a Google translation (Google, Mountain View, CA) of the text and tables, we 
were able to obtain sufficient economic information and thus included it in our review. In 
all, the 6 publications came from 6 different countries: the US [36], the UK [37], Finland 
[38], Vietnam [39], Australia [40], and Argentina [41]. Although all but 2 were cost-
effectiveness studies (1 was a cost-of-illness study and 1 a cost-utility analysis), they all 
included at least 2 types of economic evaluation (Table 1).
The selected studies (Table 2)
United States—A study [36] conducted in the county of Los Angeles, California, 
examined the impact on blood pressure and health care costs of a local policy to reduce 
sodium intake. The intervention was a food-procurement policy implemented by the county 
to reduce the intake of sodium in various settings. The study presented 2 policy scenarios to 
reduce the sodium content of foods: 1) reducing the sodium content of all foods in the 
settings of child care, senior meal programs, cafeterias, and mobile trucks; and 2) reducing 
sodium content by labeling foods and by promoting, subsidizing, and providing low-sodium 
food options in hospitals and in county government cafeterias. Using health impact 
assessment methods and considering the best available empirical evidence as well as the 
opinions, experience, and expectations of those who would be affected by the proposed 
policy, the authors found that if the sodium-reduction strategies were implemented, adults in 
the county would consume 233 fewer mg of sodium per day, on average, in 2010. This 
would correspond to an average decrease of 0.71 mmHg in systolic blood pressure (SBP) 
among adults with hypertension, 388 fewer cases of uncontrolled hypertension, and a 
decrease per year of $629,724 in direct health care costs.
However, the study did not provide robust data on most cost components of implementing 
the intervention, and thus there were no cost-effectiveness measures presented. Because of 
the variety of assumptions used and the intervention strategies postulated, the health benefits 
and savings in health care costs that were postulated should be considered potential at best.
United Kingdom—Using a spreadsheet model to quantify the reduction in CVD over a 
decade that would proceed from a population-wide risk-reduction program, this study [37] 
estimated the potential cost-effectiveness of such a program. Major outcomes were the 
number of cardiovascular events avoided, QALYs gained, and savings achieved in health 
care costs for a given level of effectiveness; the study also produced estimates of how much 
it would be worth spending to achieve a specific outcome.
The authors found that legislation or other measures to reduce the intake of salt by 3 g/day/
person (in a population where current mean intake was about 8.5g/day) would reduce mean 
population SBP by approximately 2.5 mmHg, prevent about 30,000 cardiovascular events 
and approximately 4,450 deaths, and produce discounted savings overall of approximately 
347 million pounds (about $684 million) over a decade, which would be equivalent to 
annual savings of approximately 40 million pounds. Thus, salt-reduction interventions that 
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cost less than 40 million pounds a year that achieved the proposed sodium reduction would 
be cost saving. Further, any intervention that achieved even a modest population-wide 
reduction in the incidence of any major cardiovascular risk factor would produce a net cost 
saving to the National Health Service of the UK while also improving health. Unfortunately, 
this paper did not detail the specific costs of particular programs.
Finland—In this study [38], a Markov model with a dynamic population structure was 
developed to present the natural history of CVD based on the most current information on 
the age- and sex-specific risk factors for CVD, dietary habits, and nutrient intake of the 
Finnish population aged 30−74 years. The authors applied the model to predict the health 
economic consequences of modest reductions in the daily intake of salt and the replacement 
of saturated fat with polyunsaturated fat in the population of interest. For the 20 years 
beginning in 2007, the model predicted that this intervention could potentially prevented 
8,000−13,000 CVD cases, and meanwhile added 26,000 to 45,000 QALYs and saved 
150−225 million euros (about $203–204 million). Thus a modest reduction in salt intake and 
replacing saturated fat with polyunsaturated fat in foods can significantly reduce the adult 
Finnish population’s burden of CVD.
In this study, costs were estimated from a societal perspective and included the direct cost of 
prevention, morbidity, rehabilitation, and production losses due to nonfatal CVD events. 
Age- and sex-specific estimates of quality of life (QoL) were used to represent the average 
QoL in the Finnish population. The dietary reduction of 1 g of salt per day was assumed to 
lower SBP by approximately 1.185 mmHg among hypertensive subjects and by 0.595 
mmHg among normotensive subjects. One shortcoming of the study is that it did not specify 
any particular intervention aimed at reducing dietary salt and intake of saturated fat, thus the 
cost of specific activities was unclear.
Vietnam—This study [39] was performed to assess the costs, health effects, and the cost-
effectiveness of a group of personal and non-personal (i.e., at the individual and population 
level) strategies to reduce CVD in Vietnam. The interventions, 23 in total, included a mass 
media campaign that advocated reduced consumption of salt and tobacco, the use of drugs 
for lowering blood pressure or cholesterol, and employing combined drug therapy for people 
at varying absolute risk of a cardiovascular event. A health education program to reduce salt 
intake was the most cost-effective measure at the population level, and treating people who 
had an SBP above 160 mmHg was the most cost-effective measure at the individual level. 
The authors asserted that a mass media education program on salt intake and a combination 
mass media program that focused on salt intake, cholesterol level, and tobacco use should be 
selected first. Among the 23 interventions considered in this study, the least costly was a 
health education program using the mass media to reduce salt intake, with a total cost per 
year of VND (Viet Nam Dong) 89 billion (equals US $0.06/person). It was also the most 
cost-effective at VND 1.9 million (US $118) per DALY averted.
In this study, costs were comprised of program and patient-related costs. Program costs were 
those incurred at the national, provincial, and district administrative levels, including 
training, program administration, and mass media, while patient costs were incurred at the 
point of delivery and consisted of diagnostic and laboratory tests, consultation, drugs, and 
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hospital and health center visits. However, the very low cost of the health education program 
merits further investigation to ensure the validity of the data.
Australia—Using a Markov simulation model, the authors of this study [40] evaluated the 
cost-effectiveness of interventions to prevent CVD in the Australia population of men and 
women aged 35−84 years. The study examined 2 interventions targeting the whole 
population: (a) a community heart health program, and (b) mandatory reduction of salt in the 
manufacture of breads, margarines, and cereals; it also examined 6 other interventions aimed 
at high-risk populations.
The authors concluded that reduction of salt in breads, margarines, and cereals is clearly the 
more effective and cost-effective strategy for the primary prevention of CVD; it produces 
larger improvements in population health, and between the two interventions considered, it 
can save the most money for the health sector. The authors asserted that to achieve best 
value for money in the primary prevention of CVD, the Australian government must take a 
tougher approach in mandating limits on salt in processed foods. One drawback to the study 
is that although it considered or included a variety of cost items from a number of sources, it 
is not clear whether these data were valid inputs into the model, especially the cost of 
mandatory salt reduction. For example, the authors did not mention the costs to government 
of implementing the policy or describe the costs to the manufacturers. These should have 
been included as intervention costs.
Argentina—This study [41] employed a simulation model to measure the impact of 
policies on heart disease in Argentina in order to predict trends in incidence, prevalence, 
mortality, and cost for CVD in the population aged 35–84 years. The cost of intervention 
included the cost of human resources, transportation, and a mass media campaign. The 
authors estimated the cost-utility ratio of an intervention among people aged ≥35 years that 
involved reducing the salt content of foods by 5% to 25%; these researchers modeled the 
impact and costs of a 3-g daily reduction in dietary salt intake by reducing the salt in 
processed food and the amount of salt that participants added to foods over a 10-year period.
In the high-impact scenario, the intervention generated a net savings of US $3.77 billion and 
an increase of 656,657 QALYs; in the low-impact scenario these figures were US $2.08 
billion and 401,659 QALYs. It was estimated that there would be a 24.1% reduction in the 
incidence of heart disease, 21.6% in acute myocardial infarction, 20.5% in stroke, 19.9% in 
mortality from heart disease, and 6.4% in all-cause mortality. Benefits were observed for 
both genders and for all age groups. Thus, implementing this strategy to reduce salt intake 
would produce a very positive impact in terms of QALY gains and savings in the use of 
economic resources. But this study did not present the variations of cost of interventions 
between high-impact and low-impact scenarios.
Summary and conclusions
Five of the 6 studies that we reviewed listed the cost components of the intervention to at 
least some extent, but none of them used robust cost data. In the US study, which involved a 
local food-procurement policy to reduce sodium intake, the cost of implementation was only 
based on the literature as well as data gathered from interviews with 30 agency 
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representatives and food vendors [36]. In the study from Finland [38], which involved a 
Markov model and not an actual intervention, the authors used a societal perspective to list 
the costs of prevention efforts, morbidity, rehabilitation, and loss of production due to 
nonfatal CVD events. These are not the estimated costs of an intervention to reduce salt 
intake, however. In the Vietnam study, for mass media campaigns (one of the options), the 
program costs included training, program administration, and mass media [39]. The cost 
estimates were based largely on expert opinion. In the Australia study [40], the costs of 
mandatory salt reduction were the costs of legislative changes and enforcement. Estimates 
for all these costs came from other studies or various sources. In the Argentina study, the 
costs of an intervention to reduce sodium intake included human resources, biochemical 
analysis of food, transportation, and a mass media campaign [41]. However, the study did 
not vary the cost when health outcome changed from low-impact to high-impact scenarios. 
In the UK, the study authors pointed out that no detailed specific costs of particular 
programs were available [37].
Although 5 of the 6 studies listed cost categories for the intervention(s), all of the cost data 
were incomplete. This shortcoming, in turn, may have limited the robustness of the results 
for cost-effectiveness, thereby limiting the public health implications of these studies [42]. 
There might be two major reasons on why the cost data were so inadequate? First, the 
population-wide interventions were not well defined. When the description of the 
intervention was not concrete or specific enough, it was hard for the authors to estimate 
intervention costs. Second, there might have been no economic evaluation component when 
the interventions were being developed or implemented. Further, all the economic 
evaluations were conducted after the interventions started. Thus, at best, the authors could 
only collect data on costs retrospectively.
Health outcomes in the studies we reviewed were measured by the number of CVD cases or 
deaths averted, QALYs/DALYs gained, blood pressure reduction, and health care costs 
saved. Five of the 6 studies presented the health care costs saved. This is useful information 
for advocacy purposes, but not necessary for demonstrating cost-effectiveness. Support for 
the study conclusions would have been stronger with more robust data on health care costs. 
In addition, the saving in health care costs is only a proportion of the total cost saving, as 
indirect costs such as productivity loss and the cost of informal care are often very large 
when CVD is the primary problem [4, 43]. Although the Finnish study [38] listed the costs 
of rehabilitation and lost production, it appears that the authors confused health care costs 
with the costs of intervention.
Except for the US study which was a county level investigation, all other studies claimed a 
significant health and economic benefit through population-wide sodium reduction. It is 
interesting that although the body of literature was small, the 6 studies we analyzed in detail 
included both developed and developing countries and involved the geographic regions of 
North America, South America, Europe, Australia, and Asia. This suggests that population-
wide efforts to reduce sodium intake are of interest globally. This is important because both 
hypertension and CVD affect all populations around the world. Furthermore, all evaluations 
claimed the population-wide interventions to be cost-effective or cost-beneficial. Because 
the body of literature was small and there was only one study conducted in each country, we 
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cannot derive an overall comparative measure of cost-effectiveness across countries. 
Conducting cost-effectiveness analysis using multi-country level data might be necessary.
While the results of cost-effectiveness analyses are helpful to decision makers in prioritizing 
public health interventions [44], valid cost-effectiveness evaluations must be based on 
robust data on the cost of interventions. Without high-quality data, even the best method 
cannot produce useful results. Conversely, with high-quality data on costs, a cost analysis of 
the intervention will provide decision makers and program developers a stronger economic 
argument for implementing or not implementing interventions. We also need rigorous 
estimates of the economic burden of CVD, kidney disease and other health conditions 
closely related to hypertension, especially estimates that include their indirect costs.
In conclusion, our review of recent literature allowed us to summarize the most recent 
economic evidence on reduction of sodium intake as it relates to the prevention of 
hypertension and CVD. The evidence generally supports population-wide interventions to 
achieve sodium reduction, although in each country only a single study is available on key 
intervention strategies such as reducing the salt content in manufactured foods and 
conducting mass media campaigns. The findings reinforced the findings in the literature 
[42]. In the US, all previous studies used Markov or other simulation models for their cost-
effectiveness evaluation and used medical cost saving as outcomes [45–49]. None of these 
studies mentioned the costs of intervention. Although the most recent US study [36] did not 
provide convincing cost of the intervention, authors went to extra efforts in obtaining some 
of the costs for intervention implementation from the communities. This is one good step 
toward developing practical intervention programs. In other developed countries, we did not 
find the similar efforts. In developing countries, the previous literature [50, 51] used too 
general data and methods and treated a large geographic area as a region for cost-
effectiveness evaluation. Overall, although more robust data on the costs of interventions 
and more empirical data on health outcomes (health outcomes presented in the literature 
were based on projections and simulations) are needed to conduct rigorous economic 
evaluations, population-wide sodium reduction is promising in addressing the public health 
burden of hypertension, atherosclerosis, and their sequelae.
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Table 1
Types and elements of economic evaluations for preventing cardiovascular disease by reducing sodium intake 
published during the period of January 2011 to March 2013
Lead author/country Cost analysis Cost-effectiveness analysis Cost-utility analysis Cost of illness
Gase/US [36] √ √ X
Barton/UK [37] √ X √
Martikainen/Finland [38] √ √ X √ √
Ha/Vietnam [39] √ √ X
Cobiac/Auatralia [40] √ √ X √
Ferrante/Argentina [41] √ √ X √
√ denotes that this type of economic evaluation was included in the study.
X denotes the main type of economic evaluation in the study.
No studies used cost-benefit analysis.
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